002), while the difference between treatment groups was not statistically significant in the CMML group. The median times to best response were 2.7 months (range, 1.6-18.8) in the decitabine ...

Phase 1 trial of STX-0712 to assess safety and preliminary antitumor activity of novel CCR2-CyTAC therapy in patients with CMML. "In the short period since our initial seed funding, Solu ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

(RTTNews) - Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage biopharmaceutical company, on Monday announced the resumption of patient enrollment in the investigator-initiated Phase 1/2 ...

HOUSTON - Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) has announced the resumption of patient enrollment in a Phase 1/2 clinical ... and chronic myelomonocytic leukemia (CMML).

CMML is a rare type of blood cancer. In the United States, 1 to 2 people in every 100,000 receive a CMML diagnosis each year. CMML usually affects older adults and is rare in young people.

According to his death certificate, he died of lung cancer (not a surprise) and chronic myelomonocytic leukemia (CMML), which was a total surprise. He was always a very healthy and vital man ...